{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:18:26Z","timestamp":1777461506645,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":22,"publisher":"Springer US","isbn-type":[{"value":"9781071604700","type":"print"},{"value":"9781071604717","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0471-7_27","type":"book-chapter","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T20:03:16Z","timestamp":1585252996000},"page":"373-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Absolute Quantification of Plasma Apolipoproteins for Cardiovascular Disease Risk Prediction"],"prefix":"10.1007","author":[{"given":"Betul","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeliha","family":"Selamoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nady","family":"Braidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"issue":"7","key":"27_CR1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11255-019-02170-w","volume":"51","author":"C Vlad","year":"2019","unstructured":"Vlad C, Burlacu A, Florea L, Artene B, Badarau S, Covic A et al (2019) A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. Int Urol Nephrol 51(7):1173\u20131189","journal-title":"Int Urol Nephrol"},{"issue":"7\u20138","key":"27_CR2","first-page":"559","volume":"129","author":"E Kimak","year":"2019","unstructured":"Kimak E, Nurczyk K, Skoczylas T, Duma D, Gieroba R, Solski J (2019) Fibroblast growth factor 21, epidermal growth factor receptor, interleukin 6, myeloperoxidase, lipid hydroperoxide, apolipoproteins A-I and B, as well as lipid and lipoprotein ratios as diagnostic serum biomarkers for gastric cancer. Pol Arch Intern Med 129(7\u20138):559\u2013562","journal-title":"Pol Arch Intern Med"},{"issue":"9634","key":"27_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","volume":"372","author":"MJ McQueen","year":"2008","unstructured":"McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A,\u00a0Probstfield J et al (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372(9634):224\u2013233","journal-title":"Lancet"},{"issue":"10","key":"27_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/2047487315569411","volume":"22","author":"MJ Pencina","year":"2015","unstructured":"Pencina MJ, D\u2019Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD et al (2015) Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol 22(10):1321\u20131327","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"27_CR5","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/rheumatology\/ker204","volume":"50","author":"S Ajeganova","year":"2011","unstructured":"Ajeganova S, Ehrnfelt C, Alizadeh R, Rohani M, Jogestrand T, Hafstr\u00f6m I et al (2011) Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset\u2014a prospective cohort study. Rheumatology (Oxford) 50(10):1785\u20131793","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"27_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4174\/jkss.2011.80.4.289","volume":"80","author":"HS Eo","year":"2011","unstructured":"Eo HS, Lee KB, Kim AK, Kim MH, Kim DH, Kim DI (2011) Association with inflammatory cells and apolipoproteins to the progression of atherosclerosis. J Korean Surg Soc 80(4):289\u2013296","journal-title":"J Korean Surg Soc"},{"issue":"4","key":"27_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/138920106777950834","volume":"7","author":"DW Garber","year":"2006","unstructured":"Garber DW, Handattu SP, Datta G, Mishra VK, Gupta H, White CR et al (2006) Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol 7(4):235\u2013240","journal-title":"Curr Pharm Biotechnol"},{"issue":"Suppl 1","key":"27_CR8","first-page":"S63","volume":"49","author":"B Horejsi","year":"2000","unstructured":"Horejsi B, Ceska R (2000) Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiol Res 49(Suppl 1):S63\u2013S69","journal-title":"Physiol Res"},{"issue":"2","key":"27_CR9","first-page":"186","volume":"64","author":"M Seishima","year":"2016","unstructured":"Seishima M (2016) Physiological function of apolipoproteins and atherosclerosis. Rinsho Byori 64(2):186\u2013192","journal-title":"Rinsho Byori"},{"issue":"4","key":"27_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2174\/1570161115666171010123157","volume":"16","author":"Z Zivanovic","year":"2018","unstructured":"Zivanovic Z, Divjak I, Jovicevic M, Rabi-Zikic T, Radovanovic B, Ruzicka-Kaloci S et al (2018) Association between apolipoproteins AI and B and ultrasound indicators of carotid atherosclerosis. Curr Vasc Pharmacol 16(4):376\u2013384","journal-title":"Curr Vasc Pharmacol"},{"issue":"7","key":"27_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","volume":"69","author":"R Pechlaner","year":"2017","unstructured":"Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P et al (2017) Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol 69(7):789\u2013800","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"27_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0237-y","volume":"9","author":"N Geifman","year":"2017","unstructured":"Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ (2017) Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer\u2019s disease. Alzheimers Res Ther 9(1):10. \nhttps:\/\/doi.org\/10.1186\/s13195-017-0237-y","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"27_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1194\/jlr.M500161-JLR200","volume":"46","author":"P Davidsson","year":"2005","unstructured":"Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C, Dahll\u00f6f B et al (2005) A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 46(9):1999\u20132006","journal-title":"J Lipid Res"},{"issue":"2","key":"27_CR14","first-page":"113","volume":"87","author":"O Oyelola","year":"1995","unstructured":"Oyelola O, Ajayi AA, Babalola RO, Stein EA (1995) Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. J Natl Med Assoc 87(2):113\u2013118","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"27_CR15","first-page":"23","volume":"8","author":"E Pac-Kozuchowska","year":"2002","unstructured":"Pac-Kozuchowska E, Szewczyk L, Witkowski D (2002) Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 8(1):23\u201327","journal-title":"Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw"},{"issue":"1","key":"27_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MOL.0000000000000257","volume":"27","author":"M Koch","year":"2016","unstructured":"Koch M, Jensen MK (2016) HDL-cholesterol and apolipoproteins in relation to dementia. Curr Opin Lipidol 27(1):76\u201387","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"27_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/JAD-180135","volume":"66","author":"R Ohtani","year":"2018","unstructured":"Ohtani R, Nirengi S, Nakamura M, Murase N, Sainouchi M, Kuwata Y et al (2018) High-density lipoprotein subclasses and mild cognitive impairment: study of outcome and aPolipoproteins in dementia (STOP-dementia)1. J Alzheimers Dis 66(1):289\u2013296","journal-title":"J Alzheimers Dis"},{"issue":"5\u20136","key":"27_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11357-016-9950-x","volume":"38","author":"J Tynkkynen","year":"2016","unstructured":"Tynkkynen J, Hernesniemi JA, Laatikainen T, Havulinna AS, Sundvall J, Leivisk\u00e4 J et al (2016) Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer\u2019s disease: the National Finnish population study (FINRISK). Age (Dordr) 38(5\u20136):465\u2013473","journal-title":"Age (Dordr)"},{"issue":"1","key":"27_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0352-y","volume":"15","author":"M Luo","year":"2016","unstructured":"Luo M, Peng D (2016) The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism. Lipids Health Dis 15(1):184. \nhttps:\/\/doi.org\/10.1186\/s12944-016-0352-y","journal-title":"Lipids Health Dis"},{"issue":"1\u20132","key":"27_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2009.06.003","volume":"347","author":"AN Hoofnagle","year":"2009","unstructured":"Hoofnagle AN, Wener MH (2009) The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 347(1\u20132):3\u201311","journal-title":"J Immunol Methods"},{"issue":"10","key":"27_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/14789450.2017.1374859","volume":"14","author":"I Broek van den","year":"2017","unstructured":"van den Broek I, Sobhani K, Van Eyk JE (2017) Advances in quantifying apolipoproteins using LC-MS\/MS technology: implications for the clinic. Expert Rev Proteomics 14(10):869\u2013880","journal-title":"Expert Rev Proteomics"},{"key":"27_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jprot.2016.09.011","volume":"150","author":"CA Toth","year":"2017","unstructured":"Toth CA, Kuklenyik Z, Jones JI, Parks BA, Gardner MS, Schieltz DM et al (2017) On-column trypsin digestion coupled with LC-MS\/MS for quantification of apolipoproteins. J Proteome 150:258\u2013267","journal-title":"J Proteome"}],"container-title":["Methods in Molecular Biology","Clinical and Preclinical Models for Maximizing Healthspan"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0471-7_27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T20:13:01Z","timestamp":1585253581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-0471-7_27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071604700","9781071604717"],"references-count":22,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0471-7_27","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"27 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}